Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
10
RXRX Quote, Financials, Valuation and Earnings
Last price:
$4.11
Seasonality move
:
-20.08%
Day range:
$4.11 - $4.31
52-week range:
$3.79 - $12.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
37.89x
P/B ratio:
2.05x
Volume:
24.6M
Avg. volume:
24M
1-year change:
-44.11%
Market cap:
$2.1B
Revenue:
$58.8M
EPS (TTM):
-$1.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$19.4M | -$0.38 | 440.82% | -39.26% | $7.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 234.42% | $14.83 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
HIMS
Hims & Hers Health, Inc.
|
$579.8M | $0.23 | 28.34% | 73.71% | $44.36 |
|
IBIO
iBio, Inc.
|
$25K | -$0.07 | -87.5% | -80.47% | $4.77 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$4.13 | $7.00 | $2.1B | -- | $0.00 | 0% | 37.89x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.26 | $29.79 | $4.6B | 17.54x | $0.00 | 0% | 4.38x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
GTBP
GT Biopharma, Inc.
|
$0.92 | $8.00 | $9.8M | -- | $0.00 | 0% | 59.35x |
|
HIMS
Hims & Hers Health, Inc.
|
$34.10 | $44.36 | $7.8B | 63.04x | $0.00 | 0% | 3.83x |
|
IBIO
iBio, Inc.
|
$1.85 | $4.77 | $41.6M | -- | $0.00 | 0% | 81.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
|
7.29% | 1.657 | 3.43% | 4.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
HIMS
Hims & Hers Health, Inc.
|
65.81% | 5.905 | 8.66% | 1.49x |
|
IBIO
iBio, Inc.
|
5.55% | 1.666 | 19.65% | 8.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
|
-$22.9M | -$172.2M | -72.69% | -80.23% | -3327.58% | -$117.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
HIMS
Hims & Hers Health, Inc.
|
$365.2M | $18.2M | 13.77% | 25.63% | 3.04% | $79M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
Recursion Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns RXRX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 25.76%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About RXRX or ACAD?
Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 69.49%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 9.28%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RXRXRecursion Pharmaceuticals, Inc.1 5 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is RXRX or ACAD More Risky?
Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock RXRX or ACAD?
Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RXRX or ACAD?
Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 37.89x versus 4.38x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M ACADACADIA Pharmaceuticals, Inc.4.38x 17.54x $278.6M $71.8M
-
Which has Higher Returns RXRX or FOLD?
Amicus Therapeutics, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 10.24%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About RXRX or FOLD?
Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 69.49%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 4.09%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RXRXRecursion Pharmaceuticals, Inc.1 5 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is RXRX or FOLD More Risky?
Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock RXRX or FOLD?
Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RXRX or FOLD?
Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 37.89x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns RXRX or GTBP?
GT Biopharma, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of --. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About RXRX or GTBP?
Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 69.49%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 769.47%. Given that GT Biopharma, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RXRXRecursion Pharmaceuticals, Inc.1 5 0 GTBPGT Biopharma, Inc.1 0 0 -
Is RXRX or GTBP More Risky?
Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock RXRX or GTBP?
Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RXRX or GTBP?
Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 37.89x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns RXRX or HIMS?
Hims & Hers Health, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 2.63%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.
Company Gross Margin Earnings Per Share Invested Capital RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B HIMSHims & Hers Health, Inc.60.97% $0.06 $1.7B -
What do Analysts Say About RXRX or HIMS?
Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 69.49%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $44.36 which suggests that it could grow by 30.1%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RXRXRecursion Pharmaceuticals, Inc.1 5 0 HIMSHims & Hers Health, Inc.2 8 1 -
Is RXRX or HIMS More Risky?
Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.414, suggesting its more volatile than the S&P 500 by 141.424%.
-
Which is a Better Dividend Stock RXRX or HIMS?
Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RXRX or HIMS?
Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 63.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 37.89x versus 3.83x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M HIMSHims & Hers Health, Inc.3.83x 63.04x $599M $15.8M
-
Which has Higher Returns RXRX or IBIO?
iBio, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of -5720%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About RXRX or IBIO?
Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 69.49%. On the other hand iBio, Inc. has an analysts' consensus of $4.77 which suggests that it could grow by 157.66%. Given that iBio, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RXRXRecursion Pharmaceuticals, Inc.1 5 0 IBIOiBio, Inc.6 0 0 -
Is RXRX or IBIO More Risky?
Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.459%.
-
Which is a Better Dividend Stock RXRX or IBIO?
Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RXRX or IBIO?
Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are larger than iBio, Inc. quarterly revenues of $100K. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than iBio, Inc.'s net income of -$5.7M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 37.89x versus 81.77x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M IBIOiBio, Inc.81.77x -- $100K -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
